Jonathan E. Lim, M.D.
Managing Partner and Founder
Jonathan E. Lim, MD, is a physician-turned-entrepreneur, investor, and philanthropist at City Hill, an impact-minded investment firm. Jonathan serves as Managing Partner of City Hill Ventures, LLC, which he launched in December 2010 and is dedicated to founding, funding, and leading innovative, mission-driven start-up companies. He serves as Co-President of City Hill Foundation, which he launched with his wife in December 2011 and is dedicated to grant-making and advising non-profit organizations.
From 2003 to 2018, Jonathan led four biotechnology start-up companies that collectively delivered novel therapies for the benefit of patients globally, raised ~$1 billion, and generated over $4 billion of shareholder value: President, CEO, and Chairman then Board Director of Halozyme Therapeutics, Inc. (NASDAQ: HALO) from May 2003 to December 2010; Chairman, CEO, and Co-Founder of Eclipse Therapeutics, Inc. from March 2011 to its September 2012 acquisition by Bionomics Ltd. (ASX: BNO) for a multiple of invested capital; Chairman, President, CEO, and Co-Founder of Ignyta, Inc. from August 2011 to its February 2018 acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) for a total transaction value of US$1.7 billion and subsequent integration into Roche and Genentech in July 2018; and Chairman and Co-Founder of Bonti, Inc. from August 2015 to its October 2018 acquisition by Allergan plc (NYSE: AGN) for an upfront payment of US$195M and additional potential commercial milestone payments.
Jonathan is an advisor to non-profit organizations, including Stanford University, UC San Diego, The Scripps Research Institute, and UrbanLife. Jonathan’s prior experience also includes management consulting at McKinsey & Company, NIH Postdoctoral Fellowship at Harvard Medical School and the Dana Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. He has B.S. and M.S. degrees from Stanford, an M.D. from McGill, and an M.P.H. from Harvard.
Zachary Hornby serves in operating roles in City Hill portfolio companies and is currently Chief Operating Officer at Ignyta,Inc. He brings over ten years of life sciences business experience to Ignyta. Prior to joining Ignyta, Zach was senior director of business development at Fate Therapeutics where he was responsible for pharmaceutical partnerships and non-dilutive funding. Zach has also served in various business and commercial roles at Halozyme Therapeutics, Neurocrine Biosciences and TKT (now Shire Human Genetic Therapies), and was a life sciences consultant at L.E.K. Consulting. Zach holds B.S. and M.S. degrees in biology, with a concentration in neuroscience, from Stanford University and an M.B.A. from Harvard Business School.
Karen Gilmore, CPA
Karen Gilmore joined City Hill Ventures in early 2011 as Controller and has supported multiple portfolio companies of City Hill including Eclipse Therapeutics, Inc., Ignyta, Inc. and Medenovo. She has over 25 years’ experience in leadership roles in medical device, pharmaceutical, financial services/venture funds, technology and manufacturing. Currently, Karen provides CFO and Controller level consulting to small scale start-ups and small corporations. Karen began her career as an auditor with Coopers & Lybrand (currently PriceWaterhouseCoopers). She has a Bachelor of Science degree from California State Polytechnic University, Pomona and is a Certified Public Accountant.